21:46 , Dec 1, 2017 |  BC Week In Review  |  Clinical News

JnJ begins Phase IIb trial for mosaic HIV vaccine

Johnson & Johnson (NYSE:JNJ) said it began the first trial designed to test the efficacy of a mosaic-based vaccine to prevent HIV infection. The Phase IIb trial -- Imbokodo -- is co-funded by the Bill...
00:20 , Dec 1, 2017 |  BC Extra  |  Clinical News

J&J begins Phase IIb trial of mosaic HIV vaccine

Johnson & Johnson (NYSE:JNJ) said it began the first trial designed to test the efficacy of a mosaic-based vaccine to prevent HIV infection. The Phase IIb trial -- Imbokodo -- is co-funded by the Bill...
07:00 , Aug 8, 2016 |  BC Week In Review  |  Clinical News

Ad26: Phase I/IIa started

Johnson & Johnson’s Janssen Vaccines & Prevention B.V. unit began a double-blind, placebo-controlled, international Phase I/IIa trial to compare intramuscular doses of Ad26.Mos4.HIV vs. Ad26.Mos.HIV at weeks 0 and 12 plus booster doses of either...